TrialsgrambetaRCTs are beautiful

EMPEROR-Preserved

2021

Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved EF

In 5,988 patients with HFpEF (EF > 40 %), empagliflozin reduced HF hospitalisation or CV death compared with placebo.

Result

Efficacy: HF hospitalisation or CV deathHR 0.79 (95% CI 0.69-0.90) · P < 0.001

Below 1 favours empagliflozin, above 1 favours placebo.

Event rates
Absolute difference
3.3 points
NNT
31

Absolute difference and NNT are derived from the event rates.

Also reported: Driven primarily by HF hosp.

Original publication
Subtopic
SGLT2 inhibitors
Design
Double-blind RCT
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
Anker SD, et al. N Engl J Med. 2021;385(16):1451-1461.doi 10.1056/NEJMoa2107038

Discussion & critique

First unambiguous pharmacological win in HFpEF. Benefit attenuates at very high EF (> 65 %) in pooled analyses. No mortality reduction.

Discussed in podcasts